Article

Early Risk Prediction of BCR-ABL Kinase Domain Acquired Mutations in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

2021-02-04

Abstract excerpt

<title>Abstract</title> <p>Tyrosine kinase inhibitors (TKI) resistance is a predominant cause of therapy failure of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The mutation in the BCR-ABL kinase domain, as the indicator of drug resistance, suggested recurrence and poor prognosis. Our data aimed to evaluate the factors having significant roles in the prognostic value of the acquired BC...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 38bcd8a9-e68c-518b-a70c-8b3d8c1dfde2
DOI: 10.21203/rs.3.rs-170587/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Early Risk Prediction of BCR-ABL Kinase Domain Acquired Mutations in Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaDOI 10.21203/rs.3.rs-170587/v1Read

BCR-ABL (Ph)-like acute leukemia-Pathogenesis, diagnosis and therapeutic options.Semantic proximity Read

Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in AdultsSemantic proximity Read

[Clinical and laboratory characteristics and treatment option for Philadelphia positive acute lymphoblastic leukemia patients with ABL kinase domain mutations].Semantic proximity Read

Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse.Semantic proximity Read

Susceptibility Of Ph-Positive All To Tki Therapy Associated With Bcr-Abl Rearrangement Patterns: A Retrospective AnalysisSemantic proximity Read

Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.Semantic proximity Read

Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia?Semantic proximity Read

Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemiaSemantic proximity Read

How has the management of Ph+ acute lymphoblastic leukemia (ALL) changed over the years.Semantic proximity Read

Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challengesSemantic proximity Read

T315I mutation in Ph-positive acute lymphoblastic leukemia is associated with a highly aggressive disease phenotype: three case reports.Semantic proximity Read

Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in ChildhoodSemantic proximity Read